Industry Briefing
A single destination for timely, editor-curated robotics news from around the world.
AI Discovery Pipeline Identifies Tuberculosis Drug Targets
Researchers have identified five novel inhibitors of the MenT3 toxin, a significant breakthrough in the fight against tuberculosis. This discovery was made possible through an innovative machine learning and simulations pipeline, which allowed scientists to analyze potential treatments more efficiently. The findings, announced in October 2023, highlight the potential for these inhibitors to provide new therapeutic options for tuberculosis, a disease that continues to pose a global health challenge. By leveraging advanced computational techniques, the research team was able to pinpoint compounds that could effectively target the MenT3 toxin, which plays a crucial role in the bacterium's pathogenicity. This development not only opens new avenues for treatment but also underscores the importance of integrating technology in drug discovery efforts.
Roche Scales NVIDIA AI Factories Globally to Accelerate Drug Discovery, Diagnostic Solutions and Manufacturing Breakthroughs
Roche has announced the deployment of over 3,500 NVIDIA Blackwell GPUs across its global operations, significantly enhancing its research and development productivity, next-generation diagnostics, and manufacturing efficiencies. This strategic move aims to integrate advanced computing capabilities throughout the entire value chain, thereby accelerating innovation and improving operational performance. The initiative reflects Roche's commitment to leveraging cutting-edge technology to drive advancements in healthcare and streamline its processes.
From Radiology to Drug Discovery, Survey Reveals AI Is Delivering Clear Return on Investment in Healthcare
NVIDIA has released its second annual report on the impact of artificial intelligence in healthcare, highlighting the rapid advancements across various sectors, including radiology, drug discovery, and medical device manufacturing. The report emphasizes how AI technologies are transforming treatment methods through the use of digital twins, which create virtual representations of patients to enhance personalized care. This development comes at a time when the healthcare industry is increasingly seeking innovative solutions to improve patient outcomes and streamline operations. By leveraging AI, healthcare providers can analyze vast amounts of data more efficiently, leading to faster diagnoses and more effective treatments. The findings underscore the growing importance of AI as a catalyst for change in the healthcare landscape, aiming to address challenges such as rising costs and the need for improved healthcare delivery.
CEOs of NVIDIA and Lilly Share ‘Blueprint for What Is Possible’ in AI and Drug Discovery
NVIDIA and Eli Lilly are collaborating to create a framework aimed at revolutionizing drug discovery, as announced during a recent fireside chat. NVIDIA's founder and CEO, Jensen Huang, discussed this initiative with Lilly's chair and CEO, Dave Ricks, highlighting the potential advancements in pharmaceutical research. The event took place on Monday, underscoring the companies' commitment to leveraging technology to enhance the efficiency and effectiveness of drug development. This partnership seeks to harness NVIDIA's expertise in artificial intelligence and computing power to accelerate the discovery process, ultimately aiming to bring innovative treatments to market more swiftly. By combining their resources and knowledge, both companies aspire to set a new standard in the industry, addressing the growing need for faster and more effective drug discovery methods.
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI
NVIDIA and Eli Lilly and Company have launched an innovative AI co-innovation lab aimed at addressing persistent challenges within the pharmaceutical sector. Announced today, this collaboration seeks to leverage artificial intelligence to enhance drug development processes and improve patient outcomes. By combining NVIDIA's advanced AI technology with Eli Lilly's expertise in pharmaceuticals, the lab is positioned to pioneer solutions that could transform the industry. The initiative reflects a growing trend in healthcare to integrate cutting-edge technology in order to streamline operations and accelerate the discovery of new treatments.
NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery
NVIDIA has unveiled a significant expansion of its BioNeMo™ platform, an open development system designed to facilitate lab-in-the-loop workflows aimed at advancing AI-driven biology and drug discovery. This announcement was made today, reflecting NVIDIA's commitment to enhancing research capabilities in the life sciences sector. By integrating AI technologies with biological research, the platform aims to streamline the drug discovery process, allowing scientists to leverage advanced computational tools to accelerate their findings. The expansion is expected to foster collaboration among researchers and institutions, ultimately driving innovation in the field of biotechnology.
Robotics needs a service framework.
RSF defines a common language for robot service capability, lifecycle operations, certification pathways, and service-provider networks.
Join the RobotToday community on LinkedIn
Daily robotics news, in-depth analysis, conference highlights, and discussions with professionals worldwide.
